Related Experiment Video
Updated: Jun 21, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
New and experimental therapies for HCV
Arema A Pereira1, Ira M Jacobson
1Weill Cornell Medical College, Center for the Study of Hepatitis C, New York, NY 10021, USA.
Abstract:
Despite improvements to treatments for HCV infection, almost half of patients cannot be cured with standard combination therapy (pegylated interferon alpha and ribavirin). The HCV life cycle offers a number of potential targets for molecular therapy, and several specifically targeted antiviral therapies for HCV (STAT-Cs) are in preclinical and clinical stages of development. Evidence to date suggests that monotherapy with any antiviral drug is unlikely to eradicate HCV infection. Combination therapy with interferon and ribavirin is necessary for the augmentation of antiviral drug activity and/or prevention of drug resistance. Results from clinical trials carried out in the past few years on STAT-C agents in combination with standard therapy with peginterferon and ribavirin provide great promise of higher rates of sustained virological response and, potentially, shorter duration of therapy than standard therapy alone achieves. Although pegylated interferon and ribavirin are likely to remain a cornerstone of therapeutic regimens in the short term, combinations of antiviral drugs of different classes, possibly along with novel agents that target host factors and modulate viral replication or augment antiviral defenses, offer the eventual possibility of interferon-free regimens.
Insights
New antiviral therapies show promise for curing Hepatitis C virus (HCV) infection when combined with standard treatments. These targeted therapies may lead to higher cure rates and shorter treatment durations for patients with HCV.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Standard Hepatitis C virus (HCV) treatment (pegylated interferon alpha and ribavirin) has limitations, with nearly half of patients not achieving a cure.
- The HCV life cycle presents multiple targets for novel molecular therapies, including specifically targeted antiviral therapies for HCV (STAT-Cs).
Purpose of the Study:
- To evaluate the efficacy of novel STAT-C agents in combination with standard HCV therapy.
- To explore the potential for improved treatment outcomes, including higher sustained virological response (SVR) rates and reduced therapy duration.
Main Methods:
- Clinical trials investigating STAT-C agents administered concurrently with peginterferon and ribavirin.
- Assessment of treatment efficacy based on sustained virological response rates.
Main Results:
- Clinical trials combining STAT-Cs with peginterferon and ribavirin demonstrate significant promise for enhancing antiviral activity.
- These combination therapies are associated with higher rates of sustained virological response compared to standard therapy alone.
- Potential for shorter treatment durations may be achievable with these novel regimens.
Conclusions:
- Combination therapy is essential for maximizing antiviral efficacy and preventing drug resistance in HCV treatment.
- STAT-Cs combined with standard therapy offer a promising advancement in HCV treatment, potentially leading to improved patient outcomes.
- Future HCV treatment may involve interferon-free regimens combining various antiviral drugs and host-targeting agents.
Related Concept Videos
01:25Hepatitis
01:28Viral Hepatitis I: Introduction
01:10Retrovirus Life Cycles
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Inhibitors of Viral Protein Synthesis
01:22Antiviral Nucleoside Inhibitors